Press release
United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented at the European Society of Cardiology (ESC) Congress 2022, taking place August 26-29, 2022, and the European Respiratory Society (ERS) International Congress 2022, taking place September 4-6, 2022. Both congresses will be held in Barcelona, Spain.\n\nThe presentation and posters describe completed and ongoing clinical studies of Tyvaso® (treprostinil) Inhalation Solution and Orenitram® (treprostinil) Extended-Release Tablets.\n\n“Along with the presentation of data on event-free survival in the open-label portion of the INCREASE clinical study of Tyvaso in pulmonary hypertension associated with interstitial lung disease, ERS 2022 provides us the opportunity to present additional details of the ongoing TETON studies of Tyvaso in idiopathic pulmonary fibrosis,” said Gil Golden, M.D., Ph.D., Chief Medical Officer of United Therapeutics. “Additionally, at both ERS and ESC we’re delighted to present new clinical data describing the use of Orenitram in patients on dual background therapy for pulmonary arterial hypertension.”\n\nESC posters include:\nModerated e-poster session, Sunday, August 28, 11:15 AM - 12:00 PM CET: Station 7 – Efficacy and dose-response relationship of oral treprostinil in PAH patients on monotherapy or dual background therapy. Presented by Joan Albert Barberà, M.D., Ph.D., Hospital Clínic de Barcelona.\n\nModerated e-poster session, Sunday, August 28, 11:15 AM -12:00 PM CET: Station 7 – Change in REVEAL Lite 2 and COMPERA 2.0 risk status in patients with pulmonary arterial hypertension initiating oral treprostinil on dual background therapy: a retrospective chart review. Presented by Margaret Sketch, Pharm.D., M.P.H, United Therapeutics Corporation.\n\nERS INCREASE oral presentation details:\nOral presentation, Monday, September 5, 11:55 AM - 12:00 PM CET: 8L/OA2279 – Inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease: event-free survival in INCREASE study open-label extension. Presented by Steven D. Nathan, M.D., FCCP, Inova Fairfax Hospital.\n\nERS posters include:\nThematic poster session, Monday, September 5, 8:30 AM - 9:30 AM CET: TP-23/PA193...